Friday, 16 October 2026European Markets

TGS And SUBSEA 7 Have A High Dividend Yield And Return On Equity In The Energy Sector.

Loading stream...

(VIANEWS) - TGS (TGS.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Energy sector.

Financial Asset Price Forward Dividend Yield Return on Equity
TGS (TGS.OL) kr162.30 3.28% 7.35%
SUBSEA 7 (SUBC.OL) kr116.30 3.24% 0.81%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. TGS (TGS.OL)

3.28% Forward Dividend Yield and 7.35% Return On Equity

TGS ASA provides geoscience data products and services to the oil and gas industry worldwide. The company offers geophysical data, including multi-client seismic data; geological data comprising well data products, and interpretive studies and services; and interpretation products and data integration solutions. It also provides imaging services, which include depth and time imaging; marine, land, and ocean bottom nodes; and transition zone, multi component, and 4D time-lapse processing. The company was formerly known as TGS-NOPEC Geophysical Company ASA and changed its name to TGS ASA in June 2021. TGS ASA was founded in 1981 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TGS has a trailing twelve months EPS of kr5.29.

PE Ratio

TGS has a trailing twelve months price to earnings ratio of 30.68. Meaning, the purchaser of the share is investing kr30.68 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.35%.

More news about TGS.

2. SUBSEA 7 (SUBC.OL)

3.24% Forward Dividend Yield and 0.81% Return On Equity

Subsea 7 S.A. delivers offshore projects and services for the energy industry worldwide. It provides subsea field development products and services, including project management, design and engineering, procurement, fabrication, survey, installation, and commissioning of production facilities on the seabed and the tie-back of its facilities to fixed or floating platforms or to the shore. The company also offers engineering, procurement, commissioning, and installation of subsea umbilicals, risers, and flowlines; inspection, repair, maintenance, remote intervention, and integrity management of subsea infrastructure services; conventional services comprising fabrication, installation, extension, and refurbishment of fixed and floating platforms and associated pipelines in shallow water; and hook-up services. In addition, it operates heavy lifting operations and heavy transportation services for renewables structures; and installs offshore wind turbine foundations, as well as engages in the decommissioning of redundant offshore structures. Further, the company provides remotely operated vehicles (ROVs) and tooling services to support exploration and production activities, as well as engineering and advisory services for customers in the oil and gas, renewables, and utilities industries. Subsea 7 S.A. was incorporated in 1993 and is based in Luxembourg.

Earnings Per Share

As for profitability, SUBSEA 7 has a trailing twelve months EPS of kr1.8.

PE Ratio

SUBSEA 7 has a trailing twelve months price to earnings ratio of 64.61. Meaning, the purchaser of the share is investing kr64.61 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.81%.

Sales Growth

SUBSEA 7's sales growth for the current quarter is negative 2.6%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SUBSEA 7's EBITDA is 163.63.

More news about SUBSEA 7.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com